LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Presented) A method for treating a human patient suffering from dry eye, comprising:

administering to the patient an ophthalmic composition comprising from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment said patient has a Schirmer score of less than or equal to seven millimeters per five minute.

2. (Previously Presented) The method according to claim 1, wherein prior to treatment said patient has a Schirmer score of less than or equal to five millimeters per five minutes.

3. (Canceled)

4. (Previously Presented) The method according to claim 1, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

5. (Previously Presented) The method according to claim 4, wherein said ophthalmic composition contains about 0.03% of FK506.

6. (Canceled)

7. (Previously Presented) The method according to claim 1, wherein said ophthalmic composition is an eye drop.

8. (Previously Presented) The method according to claim 7, wherein said eye drop further comprises a polyvinyl alcohol.

9. (Previously Presented) The method according to claim 7, wherein said eye drop contains about 0.03% of FK506.

10. (Previously Presented) The method according to claim 7, wherein said eye drop is administered from about one to about four times per day.

11-12. (Canceled)

13. (Previously Presented) The method according to claim 1 or 2, wherein prior to treatment said patient also has a superficial punctate keratitis (SPK) score of at least two.

14. (Previously Presented) The method according to claim 13, wherein prior to treatment said patient also has a superficial punctate keratitis (SPK) score of at least three.

15. (Previously Presented) A method for treating a human patient suffering from dry eye, comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment said patient has a superficial punctate keratitis (SPK) score of at least two.

16. (Previously Presented) A method of treating a human patient suffering from an ocular surface damage associated with dry eye, said method comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two.

17. (Previously Presented) A method of treating a human patient suffering from an ocular discomfort associated with dry eye, said method comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment the patient has a Schirmer score of less than or equal to seven millimeters per five minutes.

18. (Previously Presented) A method of treating a human patient suffering from an ocular discomfort associated with dry eye, said method comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment the patient has a superficial punctate keratitis (SPK) score of at least two.

19. (Previously Presented) A method of treating a human patient suffering from an ocular surface damage associated with dry eye said method comprising:

administering to the patient an ophthalmic composition containing from about 0.01% to about 0.1% of FK506 represented by the following structure



;

wherein prior to treatment the patient has a Schirmer score of less than or equal to seven millimeters per five minutes.

20. (Previously Presented) A method according to claim 15, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

21. (Previously Presented) A method according to claim 16, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

22. (Previously Presented) A method according to claim 17, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

23. (Previously Presented) A method according to claim 18, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.

24. (Previously Presented) A method according to claim 19, wherein said ophthalmic composition contains from about 0.01% to about 0.06% of FK506.